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Abstract
Background: The association between baseline seropositivity to human adenovirus (HAdV) type 5 and increased HIV
acquisition in the Step HIV Vaccine Study has raised questions concerning frequency of acquired and/or persistent
Adenovirus infections among adults at high risk of HIV-1 infection.
Methodology: To evaluate the frequency and pattern of HAdV shedding from the lower GI tract, we retrospectively tested
rectal swabs for HAdVs in a cohort of 20 HSV-2 positive HIV-positive Peruvian men who have sex with men (MSM)
undergoing rectal swabbing three times/week for 18 consecutive weeks, in a prospective study of HSV-2 suppression in HIV
infection. Viral DNA was extracted and amplified using a sensitive multiplex PCR assay that detects all currently recognized
HAdV types. Molecular typing of viruses was performed on selected samples by hexon gene sequencing. Baseline
neutralizing antibody titers to HAdVs 25, 226, 235 and 248 were also assessed.
Principal Findings: 15/20 individuals had HAdV detected during follow up. The median frequency of HAdV detection was
30% of samples (range 2.0% to 64.7%). HAdV shedding typically occurred on consecutive days in clustered episodes lasting
a median of 4 days (range 1 to 9 days) separated by periods without shedding, suggesting frequent new infections or
reactivation of latent infections over time. 8 of the 15 shedders had more than one type detected in follow-up. 20 HAdV
types from species B, C, and D were identified, including HAdV-5, 226 and 248, HAdV types under development as
potential vaccine candidates. 14/20 subjects were seropositive for HAdV-5; 15/20 for HAdV-26; 3/20 for HAdV-35; and 2/20
for HAdV-48. HAdV shedding did not correlate with CD4 count, plasma HIV-1 viral load, or titers to HAdV-5 or HAdV-35. The
sole individual with HAdV-5 shedding was HAdV-5 seropositive.
Conclusions: HAdV shedding was highly prevalent and diverse, including types presently under consideration as HIV
vaccine vectors. Subclinical HAdV infection of the GI tract is common among MSM in Peru; the prevalence of HAdV in the
enteric tract should be evaluated in other populations. The association between ongoing recent enteric HAdV and the
immune response to recombinant HAdV vaccines should be evaluated.
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Introduction
Human adenoviruses (HAdVs) are non-enveloped, moderate-
sized DNA viruses that cause asymptomatic infection and clinical
syndromes, including upper respiratory tract infection, conjunc-
tivitis, gastroenteritis, infections of the urinary tract, and serious
systemic infections in immunocompromised individuals [1,2].
HAdVs are grouped into seven species, A–G, and further
subdivided into at least 52 known types. HAdV shedding from
the lower GI tract may occur in healthy adults [3,4,5], but is more
common in children (where it may represent a primary infection)
[6,7,8,9], immunocompromised individuals [2], and persons with
HIV infection, particularly those with symptomatic infection and
low CD4 counts [3,10,11,12]. In HIV-infected individuals, HAdV
shedding has been associated with lower gastrointestinal symptoms
such as diarrhea and proctitis in some [3,13,14] but not all studies
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11321[5,10,12]. However, in many cases other copathogens are also
present, and it remains unclear to what extent HAdVs other than
HAdV-40/41 cause symptomatic infection in the lower GI tract.
HAdVs have been widely explored as vector systems for the
delivery of therapeutic and immunogenic gene products because of
their ability to infect a range of mammalian host cells, their
capacity to accommodate substantial genetic inserts, and their
generally favorable safety profile. HAdV type 5 (HAd-5) has been
most extensively investigated for applications in gene therapy. In
the past ten years, recombinant HAdVs, including type 5, have
also been used as vectors in the development of vaccines against
several human pathogens, including human immunodeficiency
virus (HIV)[15], malaria [16], influenza [17], tuberculosis [18],
and Ebola virus [19].
Recentstudies have indicated that pre-existing humoral immunity
to HAdV-5 is associated with reduced immunogenicity to vaccina-
tion with recombinant Ad5 vaccines. In the Step Vaccine Study, a
phase II test-of-concept study trial of the Merck HIV-1 gag/pol/nef
vaccine,men who havesex with men (MSM) with previous exposure
to HAdV-5 through natural infection appear to have had at least
transiently increased risk of acquiring HIV after vaccination [15,20].
Themechanism(s)underlyingthisobservationremainunknown,and
may include a spurious association because of the small sample size
of the trial, or true biological phenomena such as upregulation of
HIV-susceptible target cells within mucosal tissues, and interactions
between HAdV-5 immune complexes and dendritic cells resulting in
enhanced T cell infection [21]. Recent studies also have demon-
strated cross-reactive T cell responses to many human adenoviruses
[22] (and unpublished data). These observations draw attention to
the potentially important role of natural adenovirus infections in
influencing responses to recombinant Ad vector vaccines, and
highlight the need to more clearly define the epidemiology and
virology of natural human adenovirus infections.
Several HAdV types, including HAdV-5, 226, 235 and 248
are presently under active investigation for use as novel HIV,
malaria and TB vaccine vectors [16,23,24,25,26]. To evaluate
whether natural HAdV infections are common in MSM at risk for
HIV infection, we examined patterns of HAdV shedding from the
genital and lower gastrointestinal tract and tested for preexisting
neutralizing antibodies to several proposed HAdV vaccine vectors
among HIV-infected MSM undergoing intensive longitudinal
mucosal sampling.
Methods
Ethics Statement
The human experimentation guidelines of the US Department
of Health and Human Services and the individual institutions were
followed in the conduct of the clinical research. The institutional
review boards of the University of Washington and the Asociacio ´n
Civil Impacta Salud y Educacio ´n approved the protocol.
Participants provided written informed consent and were
compensated for travel and related expenses.
Study Subjects
We retrospectively examined genital and anoscopy swab
samples obtained from a cohort study of twenty HIV positive
MSM in Lima, Peru participating in a prospective randomized,
placebo-controlled cross-over study to determine the effect of
HSV-2 suppression with acyclovir (40 orally BID) on plasma HIV
levels [27]. Study subjects were greater than 18 years of age, with
no previous anti-retroviral history and peripheral CD4 counts
.200 cells/uL. This cohort offered several advantages for the
study of HAdVs; the lengthy observation period and frequent
sampling of both the anal and genital areas permitted sensitive
detection of short episodes of subclinical infection, and a
determination of whether adenovirus infection of the genital tract
was present. Because acyclovir has no known antiviral activity
against HAdVs [28,29], the clinical interventions in this cohort
allowed an unconfounded study of the prevalence and diversity of
adenoviruses infections over time in each participant.
Clinical visits and procedures
Study subjects returned to the clinic 3 times per week for a total of
18 weeks. Swabbing of the anal and genital regions for viral
pathogens was performed by two methods. Rectal mucosal swabbing
was performed via anoscopy by placing a sterile Dacron-tipped
plastic applicator (Puritan Medical Products, Guilford, ME) against
the rectal mucosa3 to 4 cm above the squamocolumnar junction and
rotating for approximately 20 seconds. Surface swabbing of the
anogenital region was performed by rubbing the swab over the glans
and full length of the penis, the scrotum, perianal skin and completed
by inserting the swab in the anus and rotating once (360 degrees).
Rectal and anogenital swabbing was performed at each clinic visit.
To characterize viral shedding between visits, anogenital swabbing
was also self-performed by participants at home. Applicator tips were
placed in vials containing 1.0 ml proteinase K digestion buffer
(100 mM KCl, 25 mM EDTA, 10 mM Tris-HCl pH 8.0, 1%
IGEPAL) and stored at 220uC until processing by the laboratory.
Home swabs were maintained at room temperature until the nearest
clinic visit and then stored as above.
DNA extraction and real-time PCR
DNA was extracted from 200 uL of proteinase K digestion
buffer using the QIAamp 96 DNA Blood Kit (Qiagen, Inc.,
Valencia, CA) according to manufacturer instructions and eluted
in a total of 100 uL AE buffer. Ten uL of the extract was used to
amplify adenoviral DNA using a multiplex PCR assay previously
validated to detect 51 recognized HAdV types [30]. The PCR
assays were performed on blinded samples at the University of
Washington Clinical Virology Laboratories.
Table 1. Cohort demographics and clinical data.
Demographic data N
Median Age (range) 31 (22,44)
Gender–male (percent) 20 (100)
Median numbers of sex partners in the last month (range) 1 (0,10)
Median numbers of sex partners in the last 6 months (range) 4 (1,40)
Clinical data N
Number of rectal swabs 969
Median number of rectal swabs per person (range) 49 (33,51)
Median number of positive swabs per person (range) 11 (0,33)
Median percent of positive swabs per person (range) 22.8 (0,64.7)
Median per person mean Log10 Ad copies/ml (range) 3.9 (2.5,5.1)
Baseline HIV viral load (range) 4.3 (3.4,5.1)
Median CD4/mm3 at screen (range) 406 (232, 869)
Number of patients who shed adenovirus at least once 15
Demographic, clinical and virologic data obtained from 20 MSM providing
rectal swabs over 18 weeks. ‘‘Positive swabs’’ indicate swabs in which
adenovirus was detected by real-time PCR. Baseline HIV viral load provided as
log10 copies/ml plasma on day 1.
doi:10.1371/journal.pone.0011321.t001
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An aliquot of DNA from all episodes of HAdV was designated
for molecular typing based on nested PCR amplification and
sequencing of a partial region of the HAdV hexon gene [31,32];
116 such samples were submitted to the Centers for Disease
Control and Prevention laboratory performing these assays.
Predicted amino acid sequences of the hexon hypervariable
regions 1–6 (corresponding to amino acid position 192–332 of
HAdV type 1 [accession number AP_000512]) were aligned with
HAdV prototype sequences (accession numbers DQ115407-
DQ115457) using Clustal X ver. 1.83 implemented in BioEdit
ver. 7.0.9.0 [33]. Phylogenetic trees were constructed using
Figure 1. Adenoviral shedding by study day. Pattern of HAdV shedding from the lower gastrointestinal tract by study day. Y axis: Log10 HAdV
titers from rectal swab material. X-axis: study day. Outlined bars: no typing attempted. Black bars: sequence-based HAdV typing performed. Gray bars:
serotyping unsuccessful.
doi:10.1371/journal.pone.0011321.g001
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Patient ID Study Day Best matching % aa identity 2
nd best match % aa identity
Ref. strain score Ref. Strain score
1001 8/8/03 Ad14 91.4 Ad50 84.3
1001 8/15/03 Ad14 91.4 Ad50 84.3
1001 8/22/03 Ad14 91.4 Ad50 84.3
1001 9/8/03 Ad17 99.3 Ad26 81.6
1001 9/12/03 (Ad36) 81.8 Ad33 76.2
1001 9/29/03 (Ad36) 81.8 Ad33 76.2
1001 10/31/03 Ad14 91.4 Ad50 84.3
1001 11/5/03 Ad5 95.6 Ad6 62.5
1001 11/14/03 Ad14 91.4 Ad50 84.3
1001 12/8/03 (Ad36) 81.8 Ad33 76.2
1001 12/12/03 (Ad15/Ad29) 80.6 Ad17 80.2
1002 9/8/03 Ad33 100 Ad43 81.1
1002 9/15/03 Ad33 100 Ad43 81.1
1002 9/26/03 Ad27 99.2 Ad28 83.9
1002 10/3/03 Ad27 99.2 Ad28 83.9
1002 10/22/03 Ad26 92.5 Ad17 81.5
1002 11/10/03 Ad5 95.6 Ad6 62.5
1002 11/17/03 Ad26 92.5 Ad17 81.5
1002 11/21/03 Ad26 92.5 Ad17 81.5
1002 12/1/03 Ad26 92.5 Ad17 81.5
1002 12/8/03 Ad37 100 Ad13 94.8
1004 9/1/03 Ad48 95.3 Ad47 82.5
1004 9/8/03 Ad48 95.3 Ad47 82.5
1004 11/17/03 Ad48 100 Ad47 84.5
1004 11/21/03 Ad48 100 Ad47 84.5
1004 11/26/03 Ad48 100 Ad47 84.5
1005 8/18/03 Ad32 95.8 Ad9 72.3
1005 10/17/03 (Ad33) 83.9 Ad36 81.8
1005 10/22/03 (Ad33) 83.9 Ad36 81.8
1005 12/10/03 Ad1 100 Ad6 71.5
1005 12/12/03 Ad1 100 Ad6 71.5
1006 11/17/03 Ad47 90.6 Ad38 77.9
1006 11/21/03 Ad47 90.6 Ad38 77.9
1006 2/23/04 Ad47 90.6 Ad38 77.9
1006 2/27/04 Ad47 90.6 Ad38 77.9
1009 10/31/03 Ad47 90.6 Ad38 77.9
1009 11/21/03 Ad47 90.6 Ad38 77.9
1010 1/19/04 Ad34 100 Ad14 81.9
1010 1/23/04 Ad34 100 Ad14 81.9
1010 1/30/04 Ad34 100 Ad14 81.9
1010 2/6/04 Ad34 100 Ad14 81.9
1010 2/13/04 Ad34 100 Ad14 81.9
1010 2/23/04 Ad34 100 Ad14 81.9
1011 4/26/04 Ad24 97.9 Ad38 80.4
1011 5/28/04 Ad24 97.9 Ad38 80.4
1013 5/5/04 Ad20 95.1 Ad42 80.4
1014 1/23/04 Ad22 100 Ad48 73.8
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midpoint-rooted using minimum F-value optimization. Evolution-
ary distances were computed using the JTT matrix-based method
with all positions containing alignment gaps and missing data
eliminated in pair-wise sequence comparisons. For the purpose of
this study, HAdVs were typed based on the reference prototype
strain that showed the highest sequence identity score at $90%
and phylogenetic association with $90% bootstrap support.
HAdV sequences with identity scores ,90% were classified by
species, but not assigned a type [32,35]. Sequence submission to
GenBank pending manuscript acceptance.
Serum neutralization
Neutralizing antibody titers for prototype HAdVs 25, 226, 235
and 248 were determined using a modified microneutralization
assay [36]. Briefly, 50 ml of heat-inactivated serum (56uCf o r3 0m i n )
was diluted 1:10 and then serially 2-fold (Eagle’s minimal essential
medium with 10% fetal calf serum) in 4-fold replicates in a 96-well
microtiter plate. Four TCID50 units of pretitered virus in 50 mlw a s
added to each well and incubated for 1 h at room temperature after
gentle agitation. Fifty ml of A549 cell suspension (400,000 cells/ml)
was then added to each well and mixed thoroughly. After incubation
for 5 days at 37uC in 5% CO2, the plate was stained with crystal
violet. The neutralization titer was defined as the highest serum
dilution that fully inhibited 4 TCID50 units of virus.
Results
A total of 969 rectal swabs were obtained (Table 1). HAdV was
detected in 218 samples (22.5%), and 15 of 20 (75%) individuals
had HAdV detected at one or more timepoints. For 932 of the
rectal samples collected, a concomitant anogenital swab was
performed, and HAdV was detected in 97/932 (10.4%) of these
samples. In 84/97 (86.6%) of the HAdV-positive anogenital swabs,
HAdV was also detected in the corresponding rectal swab
collected on the same day. Rectal swabs were also positive on
121 of the days in which no HAdV was detected in the anogenital
swab. These data suggested that the source of the adenovirus was
invariably the enteric tract, and therefore all further analyses were
restricted to samples obtained by anoscopy.
HAdV shedding in the rectal mucosa occurred on 21.1% of
days sampled (range 2.6–52.5). Mean log10 HAdV concentration
was 4.1/ml buffer (range 2.2–8.3). The pattern of HAdV shedding
in all 15 persons in whom virus shedding was detected is shown in
Figure 1. Enteric infection was characterized by frequent clusters
or ‘‘bursts’’ of shedding. HAdV concentrations in rectal swabs
varied by episode, but were generally bell-shaped over each
‘‘cluster’’ period. Sequential infections of multiple types were
documented in 9 of the 15 shedders. Median CD4 count was
406 cells/ml (range 232–869) and mean plasma HIV-1 level was
4.3 log10 copies/ml. CD4 count and plasma HIV-1 load did not
differ between participants with and without HAdV shedding
(Mann-Whitney, p=0.349 and p=0.497, resp.). HAdV shedding
patterns did not correlate with shedding of HSV2 or cytomega-
lovirus (CMV), nor with use of oral acyclovir (data not shown).
Molecular typing was attempted on a representative subset of
samples from each shedder, selected to cover all observed shedding
episodes in this cohort (N=116 samples). Fifty samples could not
be definitively assigned to a known HAdV type due to insufficient
amplified DNA for sequencing, the presence of a mixed virus
infection that could not be resolved or, in a few cases, to significant
differences between the sequenced strain and known reference
sequences. Among the 56 positive samples successfully sequenced,
numerous HAdV types distributed among species B, C, and D
Patient ID Study Day Best matching % aa identity 2
nd best match % aa identity
Ref. strain score Ref. Strain score
1014 2/2/04 Ad22 100 Ad48 73.8
1014 3/3/04 Ad1 100 Ad6 71.5
1014 5/21/04 Ad20 100 Ad42 79.7
1017 3/26/04 Ad48 95.9 Ad47 82.5
1017 3/31/04 Ad48 95.9 Ad47 82.5
1017 4/5/04 Ad48 95.9 Ad47 82.5
1017 7/12/04 (Ad26) 87.7 Ad45 83.7
1017 7/16/04 (Ad26) 87.7 Ad45 83.7
1018 3/19/04 Ad10 93.2 Ad25 81.2
1018 3/24/04 Ad10 93.2 Ad25 81.2
1019 4/12/04 Ad32 95.8 Ad9 72.3
1019 5/24/04 Ad24 97.2 Ad38 80.4
1019 5/31/04 Ad24 97.2 Ad38 80.4
1019 7/7/04 Ad32 95.8 Ad9 72.3
1020 6/16/04 Ad1 100 Ad6 71.5
1020 6/23/04 Ad37 100 Ad13 94.8
1020 7/2/04 Ad33 100 Ad39/Ad43 81.1
Predicted partial-length hexon amino acid sequence identity with nearest and second nearest reference sequences, by subject ID and sample collection day for all
samples with available sequence data. Sequence relatedness to reference strains is calculated based the percentage of shared amino acids at each position in an
alignment of sequences. Samples with no closely matching reference strain (, 90% sequence identity to known adenoviral types) are denoted by ‘‘()’’, indicating
possible new viral types.
doi:10.1371/journal.pone.0011321.t002
Table 2. Cont.
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detected in eight subjects, while only a single type was observed in
the remaining seven individuals shedding virus. Four genetically
distinct viruses were identified that had ,90% predicted amino
acid sequence identity with the prototype viruses, and may
therefore represent new types. Three unique genetic variants of
HAdV-48 were identified in two study subjects; subject 1004 shed
one variant in September followed by a second variant in
November, 2003 (Figure 2). The most prevalent types were
HAdV-1 and 233, which were seen in three individuals. The
remaining types were each seen in one or two individuals among
the 15 shedders.
Baseline serum neutralizing antibodies to HAdV-5, 226, 235
and 248 were assessed in all study participants. Fourteen of 20
individuals (70%) were seropositive for HAdV-5; 15 of 20 (75%)
for HAdV-26; three of 20 (15%) for HAdV-35; and 2 of 20 (10%)
for HAdV-48 (Table 3).
Discussion
In this study, we examined the prevalence and shedding
patterns of HAdV from the lower gastrointestinal tract of HIV-
positive Peruvian MSM through intensive longitudinal sampling
over 18 weeks. We observed viral shedding in 75% of study
participants, who collectively yielded at least 20 different HAdV
types including four potentially new types and two additional
variants of type 48. Several previous studies have examined the
prevalence of enteric viruses in a variety of populations
[2,3,4,5,6,7,8,10,11,12,13,14,37,38,39,40,41,42,43,44]. While
HAdV infections in otherwise healthy individuals generally
manifest as transient infections with complete resolution, numer-
ous studies have demonstrated the potential for these viruses to
establish prolonged and/or latent infection in a variety of sites
including adenoidal tissue [45], peripherally circulating mononu-
clear cells [46], the urinary tract [44], the conjunctiva [47], and
the GI tract [9,11].
One striking difference between this report and prior studies is
the remarkably high prevalence of HAdV shedding observed in
our study. Earlier work has suggested shedding rates ranging from
0–4% in healthy adults and from 0–28% in selected individuals
with HIV infection. In contrast, we observed shedding in 75% of
study subjects. This large disparity is likely due to the detection
methods employed. Few studies have utilized sensitive molecular
methods and the frequent sampling entailed in this protocol; past
studies have generally relied on electron microscopy, enzyme
immunoassays and cytopathogenicity assays for detection of
HAdVs, and employed relatively sparse sampling. In our study,
HAdV shedding was episodic, occurring on only 30% of days
sampled among those excreting virus at any time. It is therefore
likely that many instances of viral shedding were missed in studies
relying on limited sampling, due to the short duration of viral
shedding episodes. We also note that in this study, we have
examined HIV-positive persons who might also manifest more
frequent or prolonged HAdV reactivity [11,48]. Additionally, we
observed that the prevalence of positive neutralizing antibody
titers to HAdV-5, HAdV-35 and HAdV-48 were consistent with
several previously published reports [24,49,50,51]. However, in
this cohort, the baseline seroprevalence to HAdV-26 was
considerably higher than in most earlier studies, with the exception
of one study reporting seroprevalence rates ranging from 12%–
88% depending on the geographic region studied [51].
In this study, we have defined several previously underappre-
ciated aspects of enteric HAdV infection, including an extremely
high prevalence of viral shedding, a high rate of serological
immunity to ‘‘rare’’ serotypes, the frequent occurrence of mixed
infections, and several new adenoviral serotypes. The methods
used in this study do not permit us to conclusively distinguish
between incident infection, persistent infection with intermittent
viral reactivation, and passive shedding of viral nucleic acids
associated with latently infected cells in the absence of viral
replication. However, in several subjects, the presence of discrete
shedding episodes with rising and falling viral loads is highly
suggestive of active replication. PCR detection of adenovirus from
the enteric tract has been shown to correlate with presence of
infectious virus in non-human primates and humans [52], and thus
the shedding we have observed in our study is likely reflect the
presence of infectious virus. Whether intermittent shedding of the
same type of HAdV in several subjects over time indicates low-
grade persistent infection or episodic reactivation of latent
infection is unclear. We also note that individuals 1002, 1004
and 1017 shed viruses for which the corresponding baseline
serologies were negative (HAdV-26, 248 and 248, respectively),
suggesting that these episodes were new infections. Sequence-
based typing of mixed infections is likely to only identify the
predominant genotype present, and novel genetic variants are
Figure 2. Phylogenetic tree of hexon sequences and reference strains. Neighbor-joining phylogenetic tree of partial length HAdV hexon
gene sequences obtained from 64 clinical samples (blue) and reference strains (red).
doi:10.1371/journal.pone.0011321.g002
Table 3. Baseline serum neutralizing antibody titers by
subject.
Subject ID Ad5 titer Ad26 titer Ad35 titer Ad48 titer
1001 .1:80 .1:80 Neg 1:10
1002 .1:80 Neg Neg Neg
1003 1:80 Neg Neg Neg
1004 .1:80 1:20 Neg Neg
1005 Neg 1:10 Neg Neg
1006 .1:80 .1:80 Neg Neg
1007 .1:80 .1:80 Neg Neg
1008 Neg .1:80 1:10 Neg
1009 1:80 1:10 Neg Neg
1010 Neg .1:80 Neg Neg
1011 Neg Neg Neg Neg
1012 1:10 .1:80 1:20 .1:80
1013 1:20 1:20 Neg Neg
1014 Neg .1:80 Neg Neg
1015 1:40 Neg Neg Neg
1016 Neg Neg Neg Neg
1017 1:20 1:40 .1:80 Neg
1018 1:40 1:40 Neg Neg
1019 1:80 1:20 Neg Neg
1020 1:20 1:40 Neg Neg
% positive 70% 75% 15% 10%
Serum neutralizing antibody titers to HAdV-35, 25, 226 and 248 in each
subject at beginning of study.
doi:10.1371/journal.pone.0011321.t003
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the true diversity of HAdV types present has been underestimated
in this study.
This study is limited by modest cohort size, relatively narrow
geographical sampling and by the limited serological data
presently available. However, our serology results suggest that
infection with ‘‘rare’’ HAdVs with and/or without persistent
shedding may be more prevalent than previously thought
[24,49,50] among certain HIV+ MSM populations, and highlight
the need to further investigate the prevalence and transmission of
HAdVs in sexually active MSM and other populations at high risk
of acquiring sexually transmitted diseases. It is presently unknown
to what extent the presence of natural adenoviral infections may
interact with vaccines based on similar strains. These results must
therefore also be considered in the context of vaccine development
and immunization efforts using adenoviral vaccine vectors.
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